Veltassa

RSS

patiromer

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Veltassa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Veltassa.

For practical information about using Veltassa, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 19/06/2019

Authorisation details

Product details
Name
Veltassa
Agency product number
EMEA/H/C/004180
Active substance
patiromer sorbitex calcium
International non-proprietary name (INN) or common name
patiromer
Therapeutic area (MeSH)
Hyperkalemia
Anatomical therapeutic chemical (ATC) code
V03AE09
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Vifor Fresenius Medical Care Renal Pharma France
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
19/07/2017
Contact address
100-101 Terrasse Boieldieu
Tour Franklin La Defense 8
Paris La Defense
Cedex 92042
Paris
France

Product information

06/06/2019 Veltassa - EMEA/H/C/004180 - II/0007

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for treatment of hyperkalaemia and hyperphosphatemia

Therapeutic indication

Veltassa is indicated for the treatment of hyperkalaemia in adults

Assessment history

How useful was this page?

Add your rating